公开(公告)号：US09750727B2

公开(公告)日：2017-09-05

申请号：US13657168

申请日：2012-10-22

申请人： Joint Stock Company “Pharmasyntez”

发明人： Aleksander Sergeevich Gushchin ,  Tatiana Ivanovna Vinogradova ,  Petr Kazimirovich Yablonskiy ,  Gennady Andreevich Batyunin ,  Natalya Vyacheslavovna Zabolotnyh ,  Svetlana Nikolaevna Vasilieva ,  Alexey Vladimirovich Maligin

IPC分类号： A61K9/00 ,  A61K9/20 ,  A61K9/36 ,  A61K31/496 ,  A61K31/4425 ,  A61K9/02 ,  A61K9/28 ,  A61K9/48 ,  A61K9/50 ,  A61K31/133 ,  A61K31/395 ,  A61K31/438 ,  A61K31/4409 ,  A61K31/47 ,  A61K31/4965 ,  A61K31/7036 ,  A61K45/06

CPC分类号： A61K31/4425 ,  A61K9/0095 ,  A61K9/02 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2846 ,  A61K9/4866 ,  A61K9/5026 ,  A61K31/133 ,  A61K31/395 ,  A61K31/438 ,  A61K31/4409 ,  A61K31/47 ,  A61K31/4965 ,  A61K31/7036 ,  A61K45/06 ,  A61K2300/00

摘要： This invention relates to the field of chemical-pharmaceutical industry, specifically a new tuberculosis treatment that contains, as an active ingredient, 4-thioureido-iminomethylpyridinium perchlorate at a therapeutically effective and safe level and pharmaceutically acceptable excipients. In addition, this treatment relates to a method of the preparation of the new drug, providing a high yield of the new treatment. The new treatment has a higher tuberculostatic activity (200 times as high) and lower toxicity (2.4 times as low), as compared to a prototype drug, and is stable during long-term storage. This medicament may be used for treating and preventing all forms of pulmonary and extrapulmonary TB by using the new treatment in combination with other TB drugs.

公开(公告)号：US20130052265A1

公开(公告)日：2013-02-28

申请号：US13657168

申请日：2012-10-22

申请人： Joint Stock Company "Pharmasyntez"

发明人： Aleksander Sergeevich Gushchin ,  Tatiana Ivanovna Vinogradova ,  Petr Kazimirovich Yablonskiy ,  Gennady Andreevich Batyunin ,  Natalya Vyacheslavovna Zabolotnyh ,  Svetlana Nikolaevna Vasilieva ,  Alexey Vladimirovich Maligin

IPC分类号： A61K31/4425 ,  A61K9/36 ,  A61K31/496 ,  A61K9/20 ,  A61K9/00 ,  A61P31/06

CPC分类号： A61K31/4425 ,  A61K9/0095 ,  A61K9/02 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2846 ,  A61K9/4866 ,  A61K9/5026 ,  A61K31/133 ,  A61K31/395 ,  A61K31/438 ,  A61K31/4409 ,  A61K31/47 ,  A61K31/4965 ,  A61K31/7036 ,  A61K45/06 ,  A61K2300/00

摘要： This invention relates to the field of chemical-pharmaceutical industry, specifically a new tuberculosis treatment that contains, as an active ingredient, 4-thioureido-iminomethylpyridinium perchlorate at a therapeutically effective and safe level and pharmaceutically acceptable excipients. In addition, this treatment relates to a method of the preparation of the new drug, providing a high yield of the new treatment. The new treatment has a higher tuberculostatic activity (200 times as high) and lower toxicity (2.4 times as low), as compared to a prototype drug, and is stable during long-term storage. This medicament may be used for treating and preventing all forms of pulmonary and extrapulmonary TB by using the new treatment in combination with other TB drugs.

摘要翻译： 本发明涉及化学药物工业领域，特别涉及一种以治疗有效和安全水平含有4-硫脲基 - 亚氨基甲基吡啶鎓高氯酸盐作为活性成分的新型结核病治疗剂和药学上可接受的赋形剂。 此外，该治疗涉及新药的制备方法，提供了高效的新治疗。 与原型药相比，新型治疗具有更高的结核性活动（200倍高）和较低的毒性（2.4倍低），并且在长期储存期间是稳定的。 该药物可用于通过与其他结核病药物联合使用新治疗来治疗和预防所有形式的肺和肺外TB。